ZenaTech’s CEO Related Party, Epazz, Engages In R&D Funded By ZenaTech, And Then Sold the Tech To Zena For 19 Times Their Book Valuation, Grossly Enriching Epazz Insiders At The Expense of Zena Shareholders
- ZenaTech (NASDAQ: $ZENA ) has advanced approximately C$28.2 million in cash to Epazz (OTC: EPAZ), controlled by ZenaTech CEO Shaun Passleym, for R&D.
- ZENA then purchased these developed assets at an inflated price from EPAZ in ZENA stock.
-EPAZ own filing states: unamortized carrying value of $2,356,495.77 immediately prior to transfer. Consideration received consisted solely of ZenaTech equity securities with an aggregate fair value of $46,498,653.23
- ZENA convertible preferred shares can convert to approximately 86 million additional common-equivalent shares, making ZENA substantially more diluted than ordinary market-data share counts suggest.
See full report here:
whitediamondresearch.com/res…
This is a prime example of investors that can't see the forest for the trees. You invested in $MBOT because you want to make money right? All these specific details your splitting hairs about is missing the big picture.
The direct quotes from the report with the anonymous surgeon was:
WDR: But in its current form and iteration, it’s not ready for that, is how I’m understanding it.
Surgeon: No. Correct. Correct. Which is why, you know, I’m not trying to be cryptic, I just also don’t want to be negative. Um, you know, but no, it’s not ready. It’s not ready to change the world yet.
WDR: Okay, interesting. Yeah, that’s interesting. I didn’t quite expect to hear that. That’s why we’re speaking on the phone right now. I’m trying to better understand. So do you think this is something you can envision in new hospitals in the near-term or you think it’s not quite ready for that?
Surgeon: Oh, man, you’re really putting me on the spot here.
Um… Ah, I mean, just from your anonymous source, you’re never gonna give up. Right? Um, you know, I, I, I, I don’t think so.
We quoted him verbatim. You can see from his stuttering and saying that he "didn't want to be negative" that he wasn't eager to go forward with his criticism, but this is the truth. This was one of our best reports yet, maybe THE best.
I fully agree with @Spinoza. The discrepancies between White Diamond’s May 14 report and the subsequent public statements by Dr. Charles Briggs and Dr. Zachary Bercu deserve serious scrutiny.
Let’s examine the actual claims:
1. Guidewire compatibility: White Diamond claimed LIBERTY was limited to 0.014-inch guidewires and could not accommodate 0.018-inch wires. Both physicians subsequently confirmed successful use of 0.014- and 0.018-inch guidewires.
2. Catheter compatibility: The physicians also confirmed compatibility with 2- and 3-French microcatheters, challenging the report’s portrayal of severe technical limitations.
3. Clinical adoption: White Diamond portrayed Dr. Briggs as essentially the only LIBERTY user at Tampa General. Briggs subsequently stated that three of seven vascular surgeons were using LIBERTY, alongside interventional radiologists.
4. Procedure time: White Diamond suggested LIBERTY added approximately 15 minutes to procedures. Briggs described improved workflow efficiency and indicated that some cases might actually be shorter.
5. Clinical capability: White Diamond characterized LIBERTY as not ready for full peripheral vascular procedures. Yet Briggs described using the system in challenging vascular interventions. While this does not establish universal procedural compatibility, it challenges the report’s sweeping negative characterization.
These are not minor disagreements about valuation. They concern fundamental claims about the product’s capabilities and actual clinical use.
Importantly, Dr. Briggs was one of the physicians White Diamond interviewed. His subsequent public statements therefore deserve particular attention.
Nobody is claiming LIBERTY’s commercial success is guaranteed. Questions about reimbursement, pricing, adoption and cash burn remain legitimate.
But legitimate financial criticism does not excuse inaccurate or misleading technical claims.
White Diamond should address these specific discrepancies, explain how its original conclusions were reached, and clarify whether corrections are warranted.
Investors deserve an evidence-based debate, not selective representations of clinical reality.
Sources:
White Diamond report, May 14, 2026:
whitediamondresearch.com/res…
Briggs & Bercu discussion, May 18, 2026:
earningscalls.dev/transcript…
Hehe that's right, keep holding $MBOT short even as the major catalysts come out and sales continue to multiply. You could have been humble and admitted it when the surgeon came out to debunk your report but failing to cover when you had your chances will be your downfall buddy.
Total disaster for $UMAC today. I don't understand this extreme sell-off. I just had a quick convo with the CEO Allan Evans, and he said there's no reason for the drop other than the Democrats winning the midterms. He also doesn't believe this affects the fundamentals of the company.
So Democrats are anti-drone?
An institutional investor just bought 2M shares at $30 a few months ago. He must have seen something.
$UMAC has earnings tomorrow after the close. Remember our interview with the CEO back in March where he said there is "infinite demand" for their drone parts. The stock later hit $34. Looking forward to an update on that infinite demand tomorrow.
Here's the report:
whitediamondresearch.com/res…
According to Oppenheimer analyst Suraj Kalia on $PLSE:
"We recently accompanied PLSE management on a West Coast NDR. Competitor stumbles (Volt 2.0 events, concerns over JNJ's EP franchise) highlight PLSE's strategic value, as discussed during our meetings. As such, we are raising our price target on PLSE to $60 from $35. To be clear, much remains to be learned about the science of nsPFA. Hence, the pivotal trial readout (due CY27) will be crucial to complementing our understanding of this new PFA modality, the durability of outcomes, and nsPFA's role in the competitive matrix."
Kalia has a decent rating on Tipranks. But he is almost doubling his PT on PLSE because of "competitor stumbles"? That doesn't sound too convincing to me.
He even says: "To be clear, much remains to be learned about the science of nsPFA. Hence, the pivotal trial readout (due CY27) will be crucial to complementing our understanding of this new PFA modality, the durability of outcomes, and nsPFA's role in the competitive matrix."
So if much still needs to be learned, why be so quick to raise the PT? Just because the stock is up here and he chooses a PT slightly above the share price?
I wouldn't be surprised to see PLSE trade all the way back down to the mid-$20s. Since the big insiders stopped buying over $20 and its risen here to the $50s without the release of additional data.
$MBOT keeps executing while the share price tells a completely different story.
LIBERTY is now cleared in Israel, a 3-year exclusive distribution agreement with Medtechnica is signed, and first orders are expected in Q4 2026.
U.S. expansion continues. International expansion is starting.
The market can ignore execution for a while — but not forever.
$PLSE has gone on a major sellside analyst blitz over the past couple weeks. They've met with Canaccord, Oppenheimer, Freedom Capital, BTIG, and Mizuho. I assume they want to sell a LOT of stock!
But who's buying at this level? Not management so far. The largest shareholder, billionaire Robert Duggan, last bought 660K shares in the open market on 5/11/26 at $19.69. The CEO last bought shares that same day, 15K shares at $19.69.
There's been no insider buying of shares over that price, as far as i can see.
From our $BZAI report:
"Blaize Holdings (BZAI) is such a blantant fraud in our view, and we find it sad that uninformed retail investors are funding it. We urge the SEC to take a hard look at this company, which has a 9 figure market cap."
Maybe the SEC took our advice?
News today:
Blaize disclosed last night that in July and August , the company and certain of its employees and members of the board received subpoenas and inquiries from the Department of Justice requesting information relating to the company's business and agreements with certain counterparties. Blaize has also received voluntary requests for information from the Securities and Exchange Commission for information substantially similar to that sought by the DOJ.
When is $ZENA gonna report Q226 earnings results? Also, they are gonna have to do an offering soon. According to dilution tracker they only have about 2 weeks worth of cash left.
One head scratcher in our opinion is $PLSE, which we were clearly wrong about and would like to learn more about what has been driving the enormous rise in share price and market value.
Gotta wonder who's buying at this price. The company is selling stock like crazy and just announced last night that they sold 1.38M shares over the past month at an average price of about $50. They replenished their ATM facility for up to another $85M worth of stock sales.
One bull emailed us the reason he thinks for its huge move:
"PLSE booked and started all there targeted US trials in less than 1/2 the time they expected .
Initial excitement was the success reported, From over 100 in EU. That within In 1 year 97% did not need another procedure !
The amount of time it takes to actually do the procedure is 5-7 seconds . No shit.
The same surgeon / can more than double what they now due in a day which is about 3.
and it’s minimally evasive .This is all on there last quarterly report. The. CTO is same that created the DaVinci Robotic tech with Bob.
They expect FDA clearance for the clamp end this quarter . Then full clearance 2nd quarter 27. The important factor is the new CEO Bob hired about 2 years ago.
He was a Snr Vp for Boston Sci / For Stategic acquisitions 15 years & in this sector 40."
Our PHD medtech analyst said in response to the bull's email:
"All BS. Enrollment speed is good, but nothing extraordinary, it is fast relative to their own expectations, which given their “stellar” clinical study history is likely conservative. Sr vp of BSX is a joke. He was in business development, which is a revolving door. Major issue with this BS, is that it does not address the $4B in market value, which is unheard of for a me-too technology of a company with 25 year's record of constant failure."
We questioned the PHD if the 5-7 seconds time per procedure and 97% didn't need another procedure are significant. He responded:
"No. These are the arguments for morons that do not understand how real clinical life works."
Let's look at this another way. We've done reports on over 50 different companies over the years. Out of those 50+, what do these 4 companies that sued us have in common?